Kisspeptin: The Master Hormone Peptide for LH, Testosterone, and Fertility

At a Glance

---

Kisspeptin may be the most clinically consequential peptide most patients have never heard of. While BPC-157, thymosin alpha-1, and the GLP-1 receptor agonists dominate integrative medicine conversations, kisspeptin sits at a uniquely powerful node in human physiology: directly upstream of the entire hypothalamic-pituitary-gonadal (HPG) axis. For physicians managing functional hypogonadism, hypothalamic amenorrhea, or anovulatory infertility, understanding this neuropeptide is no longer optional — it is becoming foundational.

What Is Kisspeptin and Why Does It Matter?

Kisspeptin is a family of neuropeptides encoded by the KiSS-1 gene (chromosome 1q32). The precursor protein is cleaved into several bioactive fragments — kisspeptin-54 (metastin), kisspeptin-14, kisspeptin-13, and kisspeptin-10 — all sharing the same C-terminal active sequence that binds the kisspeptin receptor KISS1R (formerly GPR54).

The physiological significance of kisspeptin was recognized when loss-of-function mutations in KISS1R were identified in families with idiopathic hypogonadotropic hypogonadism (IHH). These individuals had normal pituitary architecture and normal gonadal reserve, yet produced no sex hormones — because the upstream GnRH pulse generator had no trigger. Conversely, gain-of-function KISS1R mutations cause central precocious puberty. This Mendelian evidence established kisspeptin as a non-redundant master regulator of reproductive endocrinology.

The HPG Axis: Where Kisspeptin Fits

The HPG axis follows a hierarchical signaling cascade:

1. Kisspeptin neurons (in the arcuate nucleus and anteroventral periventricular nucleus) fire in pulses
2. Kisspeptin binds KISS1R on GnRH neurons in the hypothalamus
3. GnRH pulses release into the portal circulation
4. The anterior pituitary releases LH (pulsatile) and FSH
5. LH stimulates Leydig cells (testosterone in men) and theca cells (androgen substrate in women)
6. FSH drives Sertoli cell function (spermatogenesis) and granulosa cell activity (folliculogenesis, estrogen, progesterone)

Kisspeptin neurons themselves receive feedback from estradiol and testosterone — both negative (suppression via negative feedback at the arcuate nucleus) and positive (the LH surge trigger via the AVPV kisspeptin population in females). This dual-feedback architecture makes kisspeptin uniquely responsive to gonadal status without being replaced by exogenous androgens the way GnRH and LH are.

Clinical Applications

1. Functional Hypogonadism in Men

Functional hypogonadism — low testosterone in the context of an otherwise intact HPG axis, without organic pituitary or testicular pathology — is increasingly prevalent among men presenting to integrative and longevity medicine practices. Chronic stress, obesity, insulin resistance, sleep disruption, and opioid use all suppress kisspeptin neuronal activity.

In this phenotype, exogenous testosterone replacement therapy (TRT) restores androgen levels but suppresses LH, FSH, and spermatogenesis through negative feedback. For men who want to preserve fertility or prefer HPG-axis restoration over suppression, kisspeptin offers a fundamentally different mechanism.

Published evidence: Single-dose kisspeptin-54 robustly stimulated LH within 60–90 minutes in healthy men and in men with hypogonadism of hypothalamic origin.

Clinical implication: Kisspeptin works only when the pituitary and gonads are intact. It is not appropriate for primary hypogonadism (Klinefelter syndrome, bilateral orchiectomy) or for secondary hypogonadism caused by pituitary adenoma or pituitary failure. The distinction is critical: a pre-treatment LH/FSH panel identifies responders.

2. Hypothalamic Amenorrhea

Hypothalamic amenorrhea (HA) — cessation of menses secondary to suppressed GnRH pulsatility from caloric restriction, overtraining, or psychological stress — is another condition where kisspeptin restoration is mechanistically sound. The kisspeptin neuronal network is highly sensitive to negative energy balance, with kisspeptin expression falling sharply during caloric deficit.

The first proof-of-concept study (Jayasena et al., Journal of Clinical Endocrinology & Metabolism, 2009) gave women with HA twice-daily SC injections of kisspeptin-54 (6.4 nmol/kg) for 2 weeks. The first injection produced a large rise in LH and FSH, but by day 14 the response had largely gone (tachyphylaxis), and LH pulsatility and ultrasound measures of reproductive activity did not change. Twice-weekly injections for 8 weeks caused only partial desensitisation (Jayasena 2010), and an intravenous infusion increased LH pulsatility during 8-hour sessions (Jayasena 2014). No study has yet shown kisspeptin restoring menstrual cycles in HA.

3. PCOS — Restoring Ovulatory Pulses

Polycystic ovary syndrome involves an elevated LH/FSH ratio and excessive LH pulse frequency, partly driven by altered kisspeptin signaling and reduced progesterone sensitivity of kisspeptin neurons. This is distinct from the hypogonadal phenotypes above.

In PCOS, the therapeutic goal is not to stimulate LH (which is already high) but to normalize its pulse pattern. Emerging research suggests that antagonizing KISS1R in PCOS — or using kisspeptin to trigger a single, timed LH surge for ovulation induction — may be more appropriate than stimulatory protocols. Kisspeptin is not a licensed trigger anywhere. Its use as an alternative to HCG has been tested in phase 2 trials in women at high risk of ovarian hyperstimulation syndrome (OHSS), because it produces a shorter, more physiological LH surge (see below).

4. Ovulation Triggering in ART

This is the best-studied application of kisspeptin to date, although all of the trials come from one IVF unit (Hammersmith Hospital, London) and none has compared kisspeptin head to head with HCG. Jayasena et al. (2014) gave 53 women a single SC trigger of kisspeptin-54 at 1.6–12.8 nmol/kg and saw egg maturation at every dose. Abbara et al. (2015, Journal of Clinical Endocrinology & Metabolism) then ran an open-label, single-centre phase 2 trial in 60 women at high OHSS risk, with doses of 3.2–12.8 nmol/kg and no HCG arm. Eggs matured in 95% of women, egg yield was highest at 12.8 nmol/kg, pregnancy rates were highest at 9.6 nmol/kg, and no woman developed moderate, severe or critical OHSS. In a later phase 2 trial in 62 high-risk women, a second 9.6 nmol/kg dose 10 hours after the first improved oocyte maturation (Abbara 2017).

Doses used in the trials: a single SC injection of 1.6–12.8 nmol/kg kisspeptin-54 (most often 6.4–12.8 nmol/kg), or 9.6 nmol/kg followed by a second 9.6 nmol/kg dose 10 hours later, with eggs collected 36 hours after the first injection.

5. Sexual Function and Libido

Beyond reproductive endocrinology, KISS1R is expressed in limbic structures including the amygdala and hypothalamic nuclei involved in sexual arousal. In a human fMRI study (Comninos et al., Journal of Clinical Investigation, 2017, from the Dhillo group at Imperial College London), kisspeptin enhanced limbic brain activity in response to sexual and couple-bonding images in 29 healthy young men and lessened negative mood. Later randomised trials in men and in women with hypoactive sexual desire disorder found similar changes in sexual brain processing, and in men a rise in penile tumescence (Mills 2023; Thurston 2022). PDE5 inhibitors, by contrast, act peripherally.

This central pro-sexual effect is mechanistically separate from testosterone and represents a potential avenue for men with low libido who have already optimized testosterone. The clinical protocol here is not yet standardized; the research dose was a single intravenous infusion of kisspeptin-54 at 1 nmol/kg/h for 75 minutes.

Dosage and Administration Protocols

For informational purposes only — this summarises doses used in research and practice; it is not a prescription or individual medical advice.

Kisspeptin protocols depend heavily on the therapeutic goal:

Kisspeptin Stimulation Test (Research)

• Purpose: Probe whether the reproductive axis can be switched on, for example in delayed puberty
• Finding: In 16 children with delayed puberty, every child whose LH rose by 0.8 mIU/mL or more after kisspeptin went on to progress through puberty, and every child with a rise of 0.4 mIU/mL or less had no signs of puberty by age 18 (Chan 2020). The test predicted outcome better than GnRH-stimulated LH, inhibin B or genetic testing.
• Dose: No standard diagnostic dose exists outside research protocols. In healthy men, an intravenous bolus of kisspeptin-10 gave the largest LH rise at 1 mcg/kg (George 2011)
• Monitoring: LH before and at intervals after the dose

Continuous and Pump Delivery (Research)

• Purpose: Sustained stimulation in HA or low gonadotropin states
• Dose: Kisspeptin-54 by intravenous infusion at 0.01–1.0 nmol/kg/h in 8-hour sessions increased LH pulsatility in women with HA, with the best dose differing per woman (Jayasena 2014). Kisspeptin-10 by subcutaneous pump at 150 nmol/h, 8 hours on and 16 hours off each day, kept gonadotropins up for 12 days in healthy men; a continuous 180 nmol/h infusion lost its effect within 5 days (Yeung 2026)
• Duration: Studied for up to 12 days; longer use is untested
• Note: Requires specialised compounding and a programmable pump

Repeated Injections in HA (Research)

• Purpose: Stimulate the reproductive axis in women with HA
• Dose: Kisspeptin-54 6.4 nmol/kg SC twice daily for 2 weeks; the LH response was largely gone by day 14 (Jayasena 2009). The same dose twice weekly for 8 weeks caused only partial desensitisation (Jayasena 2010)
• Monitoring: LH, FSH, estradiol, ultrasound

Single Ovulation Trigger

• Purpose: IVF trigger in women at high OHSS risk
• Dose: Kisspeptin-54 1.6–12.8 nmol/kg SC as a single dose (highest egg yield at 12.8, highest pregnancy rates at 9.6 nmol/kg), or 9.6 nmol/kg with a second 9.6 nmol/kg dose 10 hours later
• Timing: When leading follicles reach ≥18 mm
• Oocyte retrieval: 36 hours after the (first) injection

Protocol table

Units and what the community dose means. Research doses are weight-based and mostly in nmol/kg of kisspeptin-54, given intravenously. For kisspeptin-10 (molecular weight about 1,302 g/mol), 1 mcg/kg is roughly 0.77 nmol/kg, or about 80 mcg for an 80 kg man. The 100-200 mcg community shot therefore sits close to the intravenous bolus that gave the largest LH rise in healthy men, but it is given under the skin, where no trial has tested it as a repeated dose.

Desensitisation is the central dosing problem. Twice-daily kisspeptin-54 left women with hypothalamic amenorrhoea with almost no LH response by day 14, and FSH responsiveness was nearly gone by day 2. Twice-weekly dosing caused only partial desensitisation over 8 weeks. In men, a continuous subcutaneous infusion kept testosterone up for 5 days while LH and FSH fell back to placebo levels, whereas 8 hours on and 16 hours off kept gonadotropins raised for 12 days. That is the logic behind the 1-3 times weekly community pattern, though nobody has tested that exact schedule.

Technique, reconstitution and storage are in the peptide injection guide.

What people report: what works and what doesn’t

Sources: the aggregated community data set (Peptide Protocol Wiki, 20 reports), the reference summaries at Peptide DB and Outliyr, and the trials above. The community data set is small, so these are thin patterns, not proof.

Reported to work

• An LH and testosterone rise on bloodwork, when people test in the hours after a dose. This is the one effect the trials show reliably, starting within 30 minutes of an intravenous dose.
• Preserved testicular size and function in men on TRT using 100-200 mcg 1-3 times a week. Plausible from the mechanism, since kisspeptin drives the body’s own LH, but no trial has studied kisspeptin alongside testosterone therapy.
• Libido, reported occasionally, including on the daily low-dose pattern. The trials found that a single 75-minute infusion changed sexual brain processing and increased penile tumescence by up to 56% over placebo in men with low desire (Mills 2023); repeated home use has not been studied.

Mixed or unclear

• Who responds. Effects depend heavily on baseline hormone status. Kisspeptin needs a working hypothalamus-pituitary-testis chain, so it does nothing useful in primary testicular failure.
• Long-term use. The acute effect is well documented; what repeated injections do over months is not, and the community sources say so themselves.
• Daily dosing. Some users run 100 mcg daily; the trial data on desensitisation and one of the reference sources argue against it.

Reported not to work, or disappointing

• A lasting rise from frequent dosing. Twice-daily or continuous exposure blunts the LH response within days in the trials, which is the most likely explanation when a protocol seems to stop working.
• Side effects: the community sources list few, and the trials describe kisspeptin as well tolerated, with no adverse effects observed in the 8-week twice-weekly study. The unknowns are product quality and long-term safety; FDA placed kisspeptin-10 in 503A category 2 in 2023, citing possible immunogenicity and limited safety information.
• Access. The community data set notes that restricted compounding limits access, which pushes people towards unregulated vials.

What a properly designed trial would need to show: a randomised, placebo-controlled trial of 12 weeks or longer in men with functional low testosterone, comparing subcutaneous kisspeptin-10 at the 100-200 mcg doses used in practice and at different intervals, with serial LH, FSH and testosterone, semen analysis, symptom scores, and testing for antibodies.

Kisspeptin vs. HCG, Enclomiphene, and GnRH Analogs

Understanding where kisspeptin fits clinically requires comparison with established alternatives:

For men who want to maintain fertility while optimizing testosterone, the evidence currently favors enclomiphene as the most accessible option. Kisspeptin is a more physiological but less commercially available alternative. For IVF patients at high OHSS risk, kisspeptin is a promising trigger in phase 2 trials, but it has not been compared head to head with HCG and is not licensed for this use.

Who Should — and Should Not — Consider Kisspeptin

Potential candidates:

• Men with functional hypogonadism (low T with measurable LH) who refuse or are ineligible for TRT
• Men on TRT who wish to restore fertility without transitioning entirely off TRT
• Women with hypothalamic amenorrhea who have failed nutritional and psychological rehabilitation
• Women at high OHSS risk in ART cycles needing an alternative ovulation trigger
• Men with psychogenic low libido and intact testosterone who have not responded to PDE5 inhibitors

Contraindications:

• Primary gonadal failure (kisspeptin will not work; the signal cannot be amplified where the target organ is absent)
• Hormone-sensitive malignancy (breast, ovarian, prostate, endometrial): kisspeptin will drive gonadal steroid production
• Active pituitary disease causing secondary hypogonadism at the pituitary level
• Women with active OHSS (if kisspeptin is being considered for ovulation trigger)

Monitoring Parameters

When using kisspeptin clinically, a structured monitoring panel is essential:

Baseline (before starting):

• LH, FSH, total testosterone (or estradiol in women), SHBG, prolactin
• Pituitary MRI if LH/FSH are both very low (to rule out pituitary adenoma)
• Testicular volume / antral follicle count (context-dependent)

At 4 weeks:

• Repeat LH, FSH, gonadal steroids
• Assess symptomatic response (libido, energy, mood, menses)

At 3 months:

• Semen analysis (men seeking fertility restoration)
• Ultrasound monitoring (women with HA on treatment)

Related Articles

• Peptide Therapy for Women: Hormones, Healing, and Longevity
• Sermorelin Guide: Growth Hormone Axis Optimization
• Ipamorelin: The Cleanest Growth Hormone Secretagogue
• Hormone Optimization in Men: The Complete Testosterone Framework
• Best Peptides for Healing: A Clinical Hierarchy
• Gonadorelin: GnRH, Pulse Timing, and the hCG Substitution Problem
• Intranasal Oxytocin: A Famous Effect That Keeps Failing Replication